Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers
© Menkiszak et al. 2016
Received: 26 November 2015
Accepted: 19 February 2016
Published: 29 February 2016
There are no effective methods of diagnosis of early-stage ovarian cancer. Conservative care over patients at high risk of ovarian and breast cancers is ineffective. Prophylactic surgery is considered the best prophylaxis among BRCA1/BRCA2 carriers.
One hundred ninety-five patients, carriers of one of three most common mutations of the BRCA1 gene (Am J Hum Genet: 66: (6)1963-1968, 2000) in the Polish population (5382insC, 4153delA and C61G), who undergone prophylactic salpingo-oophorectomy. The study group consisted of consecutive mutation carriers living in Poland, in the West Pomeranian province. Histopathological examination of the surgical material failed to reveal presence of malignancy.
During follow-up we diagnosed two peritoneal cancers and 14 breast cancers. Diagnosis of breast cancer before prophylactic surgery increased the risk of peritoneal cancer almost three times. Time from diagnosis of breast cancer to prophylactic surgery increased the risk of peritoneal cancer after prophylactic surgery. This was strongly expressed (HR = 5.0; p = 0.030) in cases of over five-year-long delay in prophylactic surgery. Diagnosis of breast cancer before prophylactic surgery correlated with the risk of death (p = 0.00010). Presence of 5382insC mutation decreased and C61G mutation increased the risk of peritoneal cancer (p = 0.049 vs. p = 0.013).
Occurrence of primary peritoneal cancer after prophylactic surgery is similar to that reported in international literature. Primary breast cancer occurred less often than in international literature. We suspect that the risk of development of breast cancer among BRCA1 carriers undergoing prophylactic surgery can differ in a population. The next goal should be to study the molecular basis for the risk of development of malignancies in any population. Carriers of BRCA1 gene diagnosed with breast cancer should undergo prophylactic surgery within five years from the diagnosis of breast cancer.
KeywordsProphylactic bilateral salpingo-oophorectomy Risk-reducing salpingo-oophorectomy BRCA1 Peritoneal cancer Breast cancer
At the current state of knowledge there are no effective methods enabling identification of ovarian cancer at an early stage [1–5]. Conservative methods of prevention also failed to reduce the mortality due to ovarian cancer in a group of high-risk patients – carriers of the BRCA1 or BRCA2 gene mutations [6–13]. Other methods of conservative care over high-risk of ovarian and breast cancer patients(BRCA1 or BRCA2 carriers) have proven ineffective [1, 11, 14, 15].
According to international literature prophylactic surgery, referred to as PBSO (Prophylactic Bilateral Salpingo-Oophorectomy), RRSO (Risk-Reducing Salpingo-Oophorectomy), RRBSO (risk-reducing bilateral salpingo-oophorectomy) or BSO, is currently considered the best prophylaxis among BRCA1/BRCA2 mutation carriers [1, 16–20].
In BRCA1/BRCA2 mutation carriers, PBSO/RRSO not only decreases the risk of development of ovarian cancer by 80-90 % and breast cancer by 40–50 %, but also reduces mortality due to cancer of the genital tract and overall mortality [21–24].
According to Kotsopoulos et al., salpingo-oophorectomy is equally effective in prevention of breast cancer in women after natural menopause (p = 0.006) . Moreover, prophylactic salpingo-oophorectomy protects patients with breast cancer who are also BRCA1/BRCA2 carriers from developing ovarian cancer. Metcalfe et al. demonstrated that 25 % of deaths in this group of patients, particularly with a diagnosis of stage 1 breast cancer, is caused by ovarian cancer. The fact that in this group of patients systemic treatment did not significantly influence the risk of development of ovarian cancer  is also an argument in favor of prophylactic surgery.
In this work we present the results of our observations in patients with mutation in BRCA1 gene after prophylactic genital tract surgery in relation to development of peritoneal or breast cancers. We assessed selected risk factors for peritoneal cancer and compared chosen characteristics depending on the presence or absence of breast cancer diagnosis in a group of patients before prophylactic surgery.
To assess the incidence of peritoneal and breast cancer among carriers of the BRCA1 gene mutation after prophylactic salpingo-oophorectomy.
To analyze selected risk factors for peritoneal cancer in patients after prophylactic surgery.
To assess selected characteristics among patients subjected to surgery depending on the diagnosis of breast cancer before prophylactic operation.
The material consisted of 195 patients, carriers of one of three mutations in BRCA1 gene most commonly occurring in the Polish population (5382insC, 4153delA and C61G) , subjected to prophylactic salpingo-oophorectomy. Patients underwent prophylactic surgery over a period from 15 Sept 1999 to 31 Dec 2010. Study included consecutive mutation carriers from the West Pomeranian province, Poland, treated with surgery at the Department and Clinic of Surgical Gynecology and Gynecological Oncology (adults and children) of the Pomeranian Medical University in Szczecin, who were not diagnosed with malignancy in histopathological examination of excised material. Median age of patients at the time of surgery was 47 years (31–78 years). Median follow-up time was 80 months (4–153 months).
As much as 41.03 % (80/195) of patients were treated for breast cancer before prophylactic surgery. Patients who had been treated for breast cancer before prophylactic surgery were undergoing prophylactic salpingo-oophorectomy at an older age than patients without the diagnosis of breast cancer before surgery. Both patients diagnosed with primary peritoneal cancer after prophylactic surgery, aside from salpingo-oophorectomy, had undergone hysterectomy. Proportions of specific BRCA1 mutations were the following: 65.64 % (128/195) of patients were 5382insC carriers, 24, 62 % (48/195) had C61G mutation, and 9.74 % (19/195) subjects had mutation of the 4153 DelA type. As much as 6.67 % (13/195) of patients died during follow-up.
All continuous variables were checked for normal distribution with Kolmogorov-Smirnov test. Such variables were described as means, standard deviations, medians, quartiles, as well as minimal and maximal values. Statistical differences between two groups were checked using Student’s t test or Mann-Whitney’s test. Non-continuous variables were described through absolute numbers and frequency of occurrence. Pearson’s χ 2 test or exact Fisher’s test were used to assess the relationship between non-continuous variables.
A logistic regression model was used in order to assess the risk of occurrence of a pathology depending on the presence of various factors. Results were described by relative risk (OR) with 95 % confidence interval and a p-value indicating statistical significance. In this model, probability was assessed using Pearson’s χ 2 test or Fisher’s exact two-tailed test.
Differences were considered statistically significant in all conducted tests with p < 0.05. Level of statistical significance p = 0.051-0.099 was considered a trend with borderline statistical significance.
Statistical analyses were performed using STATA 11 software (license no. 30110532736). The bioethics committee of the Pomeranian Medical University approved (ref. no. BN-001/202/03) for the research to be carried out.
Number of cancers and type of organ affected by cancer in patients followed up after prophylactic surgery
All primary breast cancers %/(n)
All breast cancers %/(n)
All primary peritoneal and breast cancers %/(n)
1.03 % (2/195)
5.64 % (11/195)
8.21 % (16/195)
II – primary
1.54 % (3/195)
2.56 % (5/195)
All breast cancers as well as primary breast cancers were diagnosed in our material more frequently than peritoneal cancer and that difference was statistically significant, with p = 0.0022 (OR = 7.46; 95 % CI: 1.67–68.29) vs. p = 0.0323 (OR = 4.67; 95 % CI: 1.10–44.10). Primary breast cancer was 2.27 times more frequent than breast cancer recurrence, but that relationship was not statistically significant (OR = 2.27; 95 % CI: 0.71–8.49).
Time of cancer diagnosis after prophylactic surgery was significantly shorter among patients with 5382insC mutation compared with C61G and 4153DelA mutations combined, p = 0.0271 (median: 23 vs. 62 months).
Risk of occurrence of peritoneal cancer in the whole group of patients (n = 195) depending on the characteristics assessed with Cox regression model
95 % CI
Breast cancer before surgery
Age at time of surgery (years)
Risk of occurrence of peritoneal cancer in the group of patients with diagnosed breast cancer before prophylactic surgery (n = 80) depending on the characteristics assessed with Cox regression model
CI 95 %
Time from diagnosis of breast cancer prior to prophylactic surgery to prophylactic surgery
Time from diagnosis of breast cancer prior to prophylactic surgery to prophylactic surgery
Years > =5 vs. <5
Age at the moment of breast cancer diagnosis in a patient before prophylactic surgery
Evaluation of selected characteristics among patients depending on the diagnosis of breast cancer before prophylactic surgery
Breast cancer before surgery
Not identified n = 115
Identified n = 80
p = 0.00010
Development of cancer
p = 0.06835
Development of peritoneal cancer
p = 0.08832
Development of breast cancer
p = 0.20318
Development of primary breast cancer
p = 0.63096
p = 0.44111
Type of mutation
p = 0.14543
p = 0.37823
In 1982 Jeanne Tobacman et al. described the first three cases of peritoneal cancer after prophylactic oophorectomy among 28 patients from families at high risk of ovarian cancer . Many studies have been published since then. Sitzmann and Wiebke  point to several important facts in one of the most recent metaanalyses evaluating, among other things, the frequency of occurrence of peritoneal cancer after salpingo-oophorectomy in patients with BRCA1/BRCA2 mutation. Firstly, a great majority of authors report the number of diagnosed peritoneal cancers at a level of 0.8–1.8 % [22, 30–36].
Casey et al. diagnosed 5 cases of peritoneal cancer among 118 carriers of BRCA1 mutation. In one case the patient had undergone oviduct-sparing surgery . Among three cases of peritoneal cancer diagnosed in BRCA1 carriers after PBSO, Mæhle et al. associated that fact with presence of ovarian tissue left behind after previous surgeries . Oliver et al. diagnosed 11.5 % (3/26 – BRCA1 mutation) of peritoneal cancers after prophylactic surgery, but the study group consisted of patients after oviduct-sparing surgery. In the second group of patients subjected to salpingo-oophorectomy the same authors did not find any cases of peritoneal cancer during the follow-up period (0/58 – BRCA1). However, researchers admit that it might have been due to very short mean follow-up time, which amounted to 12 months . Likewise, after 16 months of follow-up, Gaarenstroom et al. did not diagnose peritoneal cancer in any of 114 patients (57 patients were carriers of BRCA1 mutation) following prophylactic salpingo-oophorectomy .
Laki et al. did not find any cases of peritoneal cancer among their patients following mean follow-up time of 40 months either . Similarly, there were no cases of primary peritoneal cancer in an 8.17-year follow-up in a study by Evans et al. that included BRCA1/BRCA2 mutation carriers (160 patients, including 104 subjects with BRCA1 mutation) after salpingo-oophorectomy .
Authors who failed to find cases of peritoneal cancer after prophylactic salpingo-oophorectomy most often explain it by short follow-up time. Such an argument is no longer valid for the analysis of work by Evans et al. Small size of the group is also often given as a reason for the lack of such a finding .
In our analysis we acquired a result almost identical with regard to the frequency of diagnosis of peritoneal cancer among patients after salpingo-oophorectomy to that obtained by Rhiem et al. – 1.03 % vs. 1.09 % (2/195 vs. 1/92 – BRCA1 gene mutations). The time of the first diagnosis of peritoneal cancer was also similar – in our material it amounted to 30 months, while according to Rhiem et al. – 26 months . In our study the second peritoneal cancer was diagnosed after 62 months.
The second, very important conclusion ensuing from this research is such that after prophylactic surgery peritoneal cancer develops more frequently in BRCA1 mutation carriers. Peritoneal cancer was very rare among patients with BRCA2 mutation. In their metaanalysis, Sitzmann and Wiebke  presented results of 12 research teams and in only one study by Finsch et al. peritoneal cancer was found in a patient with a mutation in the BRCA2 gene .
However, it should be emphasized, that while there are thousands of examined patients and mean follow-up time from prophylactic surgery to the diagnosis of peritoneal cancer exceeds 6 years, the proportion of mutations in both BRCA genes found in patients with primary peritoneal cancer diagnosed after salpingo-oophorectomy has evidently changed – 28 BRCA1 vs. BRCA2 .
Due to a small number of subjects after prophylactic surgery with BRCA2 gene mutation, we did not take their data into consideration.
In our material we diagnosed 14 cases (14/195 = 7.18 %) of breast cancer, including 6 cases in patients without the diagnosis of breast cancer before prophylactic surgery, 3 cases of second primary breast cancer and 5 cases of breast cancer recurrence. Thus, primary breast cancers identified during the follow-up time constituted only 4.63 % (9/195) of all cases (Table 1).
Results obtained for primary breast cancers in our material were somewhat smaller than values reported by Casey et al. – 4.63 % vs. 5.93 % (7/118 – BRCA1 mutation) over a shorter median follow-up time – 6.67 vs. 8.3 years, respectively .
Similar overall results were obtained by Kauff et al.– 7.89 % (15/190 – BRCA1 mutation), with mean follow-up time shorter almost by half , and Powell et al. – 6.35 % (4/63) among BRCA1 carriers, with median observation time almost 1/3 shorter compared to our study. Moreover, in a detailed analysis researchers emphasize that most of these cases were breast cancer recurrences . Domchek et al. acquired significantly higher results with respect to breast cancer diagnoses among BRCA1 mutation carriers subjected to prophylactic salpingo-oophorectomy over an almost 5-year-long mean follow-up time – 13.6 % (51/374 – BRCA1). Moreover, quantitative values were comparable regardless of a diagnosis of breast cancer before prophylactic surgery .
Ramon Y Cajal et al. presented very high quantitative values – researchers diagnosed as many as 5 cases of breast cancer among 25 carriers of BRCA1 gene mutation (20 %–5/25) subjected to prophylactic salpingo-oophorectomy. In that case median follow-up time was 49 months .
Likewise, a very high (over 20 %) proportion of breast cancer diagnoses among BRCA1 mutation carriers after prophylactic bilateral oophorectomy was obtained by Shah et al. with a median follow-up time from surgery to the diagnosis of cancer amounting to 3.6 years .
Since the differing results of studies on breast cancer in BRCA1 carriers undergoing prophylactic salpingo-oophorectomy came from multi-center, multi-national trials performed in various countries: USA, Canada, Netherlands, France, Norway, Spain, Australia and New Zeeland, we believe that it is necessary to examine molecular background in all populations, particularly for such a common malignancy as breast cancer.
There were few publications on the influence of breast cancer diagnosis among BRCA1 gene mutation carriers before prophylactic surgery and the incidence of peritoneal cancer in the postoperative period. There are also few publications regarding the influence of the time from diagnosis of breast cancer to prophylactic surgery and the diagnosis of peritoneal cancer in the postoperative period.
In our material the diagnosis of breast cancer before prophylactic surgery was associated with an almost three-fold increase in the risk of peritoneal cancer. However, that correlation was not statistically significant. Domchek et al. acquired an opposite result. Peritoneal cancer was found less often in patients with BRCA1 mutation and breast cancer diagnosis before surgery than in patients without breast cancer prior to surgery – 1.18 % vs. 1.75 %. Researchers demonstrated also that prophylactic salpingo-oophorectomy decreased the risk of primary peritoneal cancer among patients without previous diagnosis of breast cancer by 70 % and in patients diagnosed with breast cancer prior to prophylactic surgery by 85 % .
In our opinion, dissimilarities in our conclusions with regard to the risk of development of peritoneal cancer among patients without the diagnosis of breast cancer prior to prophylactic surgery may ensue from different numbers of diagnosed peritoneal cancer cases – 2 vs. 10 patients in a study by Domchek et al. Moreover, in our study both patients diagnosed with primary peritoneal cancer, who had been treated for breast cancer prior to prophylactic surgery, decided to have the salpingo-oophorectomy performed after the age of 50. Therefore, surgery might no longer serve a protective role in development of peritoneal cancer postoperatively.
Continuing the subject of the influence of breast cancer diagnosis before prophylactic surgery, among six analyzed features we found only the risk of death to be statistically significant. Patient survival after prophylactic surgeries will be the subject of another publication.
The topic of the influence of BRCA1 gene mutation on examined characteristics is highly problematic to discuss. Although the type of mutation most commonly identified in Polish population - 5382insC – is also found among Jewish people, Ashkenazi Jews in particular , available literature lacks the data for discussion.
Based on the analysis of gathered material and existing literature we found that in our data the incidence of primary peritoneal cancer after prophylactic surgery is similar to that reported in international literature. What differs our material from reports in international literature is the occurrence of primary breast cancer – it was significantly less frequent. Another conclusion is that it cannot be excluded that the risk of breast cancer development among constitutional BRCA1 gene mutation carriers subjected to prophylactic surgery varies in a population. The next goal in research should be to examine molecular background with regard to the risk of malignancy in every population. It is also important that carriers of the BRCA1 gene mutation diagnosed with breast cancer should be subjected to prophylactic surgery within less than five years from the diagnosis of breast cancer, as the risk of peritoneal cancer increases significantly after that period.
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, et al. Society of Gynecologic Oncology Recommendations for the Prevention of Ovarian Cancer. Cancer. 2015;121:2108–20.View ArticlePubMedGoogle Scholar
- Howard AF, Balneaves LG, Bottorff JL, et al. Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction. Qual Health Res. 2011;21(4):502–19.View ArticlePubMedGoogle Scholar
- Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009;46(9):593–7.View ArticlePubMedGoogle Scholar
- Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6(7):e1000114.View ArticlePubMedPubMed CentralGoogle Scholar
- Gulden C, Olopade OI. Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010;194(2):309–10.View ArticlePubMedGoogle Scholar
- Goff BA, Lowe KA, Kane JC, Robertson MD, Gaul MA, Andersen MR. Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. Gynecol Oncol. 2012;24:230–5.View ArticleGoogle Scholar
- Goff BA. Ovarian cancer: screening and early detection. Obstet Gynecol Clin North Am. 2012;39:183–94.View ArticlePubMedGoogle Scholar
- Goff BA, Matthews B, Andrilla CH, et al. How are symptoms of ovarian cancer managed? A study of primary care physicians. Cancer. 2011;117:4414–23.View ArticlePubMedGoogle Scholar
- Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012;55:36–42.View ArticlePubMedGoogle Scholar
- Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008;113:484–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295–303.View ArticlePubMedGoogle Scholar
- Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012;13:285–91.View ArticlePubMedGoogle Scholar
- Andersen MR, Goff BA, Lowe KA, et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Synowiec A, Wcisło G, Bodnar L, Gasowska-Bodnar A, Szczylik C. Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers. Ginekol Pol. 2014;85(5):377–81.PubMedGoogle Scholar
- Mądry R, Markowska A. Reduction of risk of developing BRCA-dependent cancer in BRCA1/2 mutation carriers – novel approach to old paradigm. Curr Gynecol Oncol. 2010;8(3):188–99.Google Scholar
- Greene MH, Piedmonte M, Alberts D, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17:594–604.View ArticlePubMedPubMed CentralGoogle Scholar
- Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011;204(1):19.e1–6.View ArticleGoogle Scholar
- Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921–7.View ArticlePubMedGoogle Scholar
- Long KC, Kauff ND. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr Opin Oncol. 2011;23(5):526–30. Review.View ArticlePubMedGoogle Scholar
- Berek JS, Chalas E, Edelson M, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Society of Gynecologic Oncologists Clinical Practice Committee. Obstet Gynecol. 2010;116(3):733–43.View ArticlePubMedGoogle Scholar
- Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Domchek SM, Friebel TM, Singer CF, et al. Association of riskreducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1089–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222–6.View ArticlePubMedGoogle Scholar
- Górski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000;66(6):1963–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni Jr JF. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982;2(8302):795–7.View ArticlePubMedGoogle Scholar
- Sitzmann JV, Wiebke EA. Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer. JAMA Surg. 2013;148(3):285–91.View ArticlePubMedGoogle Scholar
- Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, et al. Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–22.View ArticlePubMedGoogle Scholar
- Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–15.View ArticlePubMedGoogle Scholar
- Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185–92.View ArticlePubMedGoogle Scholar
- Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, Büttner R, Ulrich U, et al. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet. 2011;283(3):623–7.View ArticlePubMedGoogle Scholar
- Kiely BE, Friedlander ML, Milne RL, Stanhope L, Russell P, Jenkins MA, et al. kConFab Investigators, Hopper JL, Phillips KA. Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. Fam Cancer. 2011;10(3):505–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011;21(5):846–51.View ArticlePubMedGoogle Scholar
- Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97(2):457–67.View ArticlePubMedGoogle Scholar
- Mæhle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin Cancer Res. 2008;14(22):7569–73.View ArticlePubMedGoogle Scholar
- Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90(8):1492–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer. 2006;16(1):54–9.View ArticlePubMedGoogle Scholar
- Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, et al. IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer. 2007;109(9):1784–90.View ArticlePubMedGoogle Scholar
- Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet. 2009;17(11):1381–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, et al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Cancer Prev Res (Phila). 2012;5(11):1291–7.View ArticleGoogle Scholar
- Ramon Y, Cajal T, Torres A, Alonso C, Fisas D, Ojeda B, et al. Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women. Cancer Epidemiol. 2011;35(1):78–82.View ArticleGoogle Scholar
- Shah P, Rosen M, Stopfer J, Siegfried J, Kaltman R, Mason B, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat. 2009;118(3):539–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8(12):3776–81.PubMedGoogle Scholar